@article{Mohr-Holland2020,
abstract = {Here we report on the final outcomes for the cohort of 103 patients, 77{\%} HIV-positive with a median (interquartile range, IQR) CD4 count of 141 (61–252) cells per mm3, from Khayelitsha, South Africa who initiated regimens containing delamanid (Dlm) for the treatment of rifampicin-resistant tuberculosis (RR-TB) from November 2015 to August 2017 [1]. The median (IQR) duration on Dlm was 6.3 (4.3–12.0) months; 54 (52{\%}) patients received Dlm for more than 6 months and 32 (31{\%}) also received a regimen containing bedaquiline (Bdq), 26 (81{\%}) of whom harboured fluoroquinolone (Fq) resistant strains. Delamanid (Dlm) containing regimens to treat RR-TB are effective, but more data on Dlm use is needed. Dlm remains an important treatment option in programmatic settings with high rates of HIV co-infection and in persons with limited treatment options. {\textless}https://bit.ly/3cVLeUq{\textgreater}},
author = {Mohr-Holland, Erika and Reuter, Anja and Hughes, Jennifer and Daniels, Johnny and Beko, Busisiwe and Makhanda, Goodman and {De Avezedo}, Virginia and Kock, Yulene and Cox, Helen and Furin, Jennifer and {Trivino Duran}, Laura and Isaakidis, Petros and Ferlazzo, Gabriella},
doi = {10.1183/13993003.00837-2020},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Mohr-Holland et al. - 2020 - Correspondence regarding Delamanid for rifampicin-resistant tuberculosis a retrospective study from South A.pdf:pdf},
issn = {13993003},
journal = {European Respiratory Journal},
keywords = {OA,fund{\_}ack,letter},
mendeley-tags = {OA,fund{\_}ack,letter},
month = {jul},
number = {1},
pages = {2000837},
pmid = {32703820},
publisher = {NLM (Medline)},
title = {{Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa"}},
url = {https://erj.ersjournals.com/content/56/1/2000837 https://erj.ersjournals.com/content/56/1/2000837.abstract},
volume = {56},
year = {2020}
}

{"_id":"mvLdXq2KoGzmiiTZd","bibbaseid":"mohrholland-reuter-hughes-daniels-beko-makhanda-deavezedo-kock-etal-correspondenceregardingdelamanidforrifampicinresistanttuberculosisaretrospectivestudyfromsouthafrica-2020","authorIDs":[],"author_short":["Mohr-Holland, E.","Reuter, A.","Hughes, J.","Daniels, J.","Beko, B.","Makhanda, G.","De Avezedo, V.","Kock, Y.","Cox, H.","Furin, J.","Trivino Duran, L.","Isaakidis, P.","Ferlazzo, G."],"bibdata":{"bibtype":"article","type":"article","abstract":"Here we report on the final outcomes for the cohort of 103 patients, 77% HIV-positive with a median (interquartile range, IQR) CD4 count of 141 (61–252) cells per mm3, from Khayelitsha, South Africa who initiated regimens containing delamanid (Dlm) for the treatment of rifampicin-resistant tuberculosis (RR-TB) from November 2015 to August 2017 [1]. The median (IQR) duration on Dlm was 6.3 (4.3–12.0) months; 54 (52%) patients received Dlm for more than 6 months and 32 (31%) also received a regimen containing bedaquiline (Bdq), 26 (81%) of whom harboured fluoroquinolone (Fq) resistant strains. Delamanid (Dlm) containing regimens to treat RR-TB are effective, but more data on Dlm use is needed. Dlm remains an important treatment option in programmatic settings with high rates of HIV co-infection and in persons with limited treatment options. \\textlesshttps://bit.ly/3cVLeUq\\textgreater","author":[{"propositions":[],"lastnames":["Mohr-Holland"],"firstnames":["Erika"],"suffixes":[]},{"propositions":[],"lastnames":["Reuter"],"firstnames":["Anja"],"suffixes":[]},{"propositions":[],"lastnames":["Hughes"],"firstnames":["Jennifer"],"suffixes":[]},{"propositions":[],"lastnames":["Daniels"],"firstnames":["Johnny"],"suffixes":[]},{"propositions":[],"lastnames":["Beko"],"firstnames":["Busisiwe"],"suffixes":[]},{"propositions":[],"lastnames":["Makhanda"],"firstnames":["Goodman"],"suffixes":[]},{"propositions":[],"lastnames":["De Avezedo"],"firstnames":["Virginia"],"suffixes":[]},{"propositions":[],"lastnames":["Kock"],"firstnames":["Yulene"],"suffixes":[]},{"propositions":[],"lastnames":["Cox"],"firstnames":["Helen"],"suffixes":[]},{"propositions":[],"lastnames":["Furin"],"firstnames":["Jennifer"],"suffixes":[]},{"propositions":[],"lastnames":["Trivino Duran"],"firstnames":["Laura"],"suffixes":[]},{"propositions":[],"lastnames":["Isaakidis"],"firstnames":["Petros"],"suffixes":[]},{"propositions":[],"lastnames":["Ferlazzo"],"firstnames":["Gabriella"],"suffixes":[]}],"doi":"10.1183/13993003.00837-2020","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Mohr-Holland et al. - 2020 - Correspondence regarding Delamanid for rifampicin-resistant tuberculosis a retrospective study from South A.pdf:pdf","issn":"13993003","journal":"European Respiratory Journal","keywords":"OA,fund_ack,letter","mendeley-tags":"OA,fund_ack,letter","month":"jul","number":"1","pages":"2000837","pmid":"32703820","publisher":"NLM (Medline)","title":"Correspondence regarding \"Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa\"","url":"https://erj.ersjournals.com/content/56/1/2000837 https://erj.ersjournals.com/content/56/1/2000837.abstract","volume":"56","year":"2020","bibtex":"@article{Mohr-Holland2020,\r\nabstract = {Here we report on the final outcomes for the cohort of 103 patients, 77{\\%} HIV-positive with a median (interquartile range, IQR) CD4 count of 141 (61–252) cells per mm3, from Khayelitsha, South Africa who initiated regimens containing delamanid (Dlm) for the treatment of rifampicin-resistant tuberculosis (RR-TB) from November 2015 to August 2017 [1]. The median (IQR) duration on Dlm was 6.3 (4.3–12.0) months; 54 (52{\\%}) patients received Dlm for more than 6 months and 32 (31{\\%}) also received a regimen containing bedaquiline (Bdq), 26 (81{\\%}) of whom harboured fluoroquinolone (Fq) resistant strains. Delamanid (Dlm) containing regimens to treat RR-TB are effective, but more data on Dlm use is needed. Dlm remains an important treatment option in programmatic settings with high rates of HIV co-infection and in persons with limited treatment options. {\\textless}https://bit.ly/3cVLeUq{\\textgreater}},\r\nauthor = {Mohr-Holland, Erika and Reuter, Anja and Hughes, Jennifer and Daniels, Johnny and Beko, Busisiwe and Makhanda, Goodman and {De Avezedo}, Virginia and Kock, Yulene and Cox, Helen and Furin, Jennifer and {Trivino Duran}, Laura and Isaakidis, Petros and Ferlazzo, Gabriella},\r\ndoi = {10.1183/13993003.00837-2020},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Mohr-Holland et al. - 2020 - Correspondence regarding Delamanid for rifampicin-resistant tuberculosis a retrospective study from South A.pdf:pdf},\r\nissn = {13993003},\r\njournal = {European Respiratory Journal},\r\nkeywords = {OA,fund{\\_}ack,letter},\r\nmendeley-tags = {OA,fund{\\_}ack,letter},\r\nmonth = {jul},\r\nnumber = {1},\r\npages = {2000837},\r\npmid = {32703820},\r\npublisher = {NLM (Medline)},\r\ntitle = {{Correspondence regarding \"Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa\"}},\r\nurl = {https://erj.ersjournals.com/content/56/1/2000837 https://erj.ersjournals.com/content/56/1/2000837.abstract},\r\nvolume = {56},\r\nyear = {2020}\r\n}\r\n","author_short":["Mohr-Holland, E.","Reuter, A.","Hughes, J.","Daniels, J.","Beko, B.","Makhanda, G.","De Avezedo, V.","Kock, Y.","Cox, H.","Furin, J.","Trivino Duran, L.","Isaakidis, P.","Ferlazzo, G."],"key":"Mohr-Holland2020","id":"Mohr-Holland2020","bibbaseid":"mohrholland-reuter-hughes-daniels-beko-makhanda-deavezedo-kock-etal-correspondenceregardingdelamanidforrifampicinresistanttuberculosisaretrospectivestudyfromsouthafrica-2020","role":"author","urls":{"Paper":"https://erj.ersjournals.com/content/56/1/2000837 https://erj.ersjournals.com/content/56/1/2000837.abstract"},"keyword":["OA","fund_ack","letter"],"metadata":{"authorlinks":{}},"downloads":0},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","creationDate":"2020-09-02T17:03:32.115Z","downloads":0,"keywords":["oa","fund_ack","letter"],"search_terms":["correspondence","regarding","delamanid","rifampicin","resistant","tuberculosis","retrospective","study","south","africa","mohr-holland","reuter","hughes","daniels","beko","makhanda","de avezedo","kock","cox","furin","trivino duran","isaakidis","ferlazzo"],"title":"Correspondence regarding \"Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa\"","year":2020,"dataSources":["Krmt6gt9ktB2s6ARh","FdCBAxFeyKEmJd8WK"]}